Abstract 478P
Background
Although available evidence establishing the impact of germline PV of DNA-repair genes in patients with luminal MBC is conflicting, the standard treatment is represented by CDK 4/6i plus ET.
Methods
In this retrospective multicenter study, HR+ HER2- MBC pts tested for gBRCA1/2 genes and who received CDK 4/6i plus ET from 1st Jan 2017 to 31th December 2021, were included. The objectives were the evaluation of outcome (primary/secondary end-points: progression free survival [PFS]/overall survival [OS]) according to gBRCA1/2 status (PV versus wild type [wt]/variants of uncertain significance [VUS]), estimated by Kaplan-Meier method. Cox model was used to assess the correlation between baseline variables and outcomes.
Results
249 pts in 13 centers were included in the study: 40 (16.1%) pts carried gBRCA1/2 PV (N=31 with gBRCA2 PV), 20 (8.0%) pts had VUS BRCA1/2, 189 (75.9%) pts were wt. Baseline charateristics were: median age 52 years (range: 26 – 83 yrs); male 2.8% (N=7; with 3 gBRCA2 PV); premenopausal 46.6% (N=116); visceral metastases 78% (N=194); ECOG PS 0 80% (N=199); 1st line CDK4/6i plus aromatase inhibitor (AI) 53% (N=132); chemotherapy (CT) before CDK4/6i plus ET 16.5% (N=41). The two groups differed for ECOG PS ≥ 1 (32.5 vs. 17.7%; p= 0.032) and previous CT (32.5% vs. 13.4%; p= 0.003). With a median follow up of 37.5 months (95%CI 31.4 – 43.5) the mPFS was 10.7 vs. 26.7 months for pts with gBRCA1/2 PV and wt, respectively (p< 0.001). Similarly, mOS was shorter for gBRCA1/2 PV pts (40.1 vs. 69.0 months; p= 0.013). After adjusting survivals for ECOG PS status and use of previous CT for MBC, the worse outcome was confirmed for pts with gBRCA1/2 PV (HR for PFS, 1.61; 95%CI: 1.09 – 2.44; p= 0.017 and HR for OS, 1.72; 95%CI: 1.01 – 2.94; p= 0.047). Among gBRCA1/2 PV pts, PARP inhibitor and CT were the treatments after CDK4/6i progression in 15.6% (N=5) and 62.5 % (N=20; 8 pts had platinum based treatment), respectively.
Conclusions
These data reported gBRCA1/2 PV as a negative prognostic factor for HR+ HER2- MBC pts treated with CDK4/6i plus ET. Different strategies are urgently needed for this subgroup of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Palazzo: Financial Interests, Personal, Advisory Board: AZ/Daiichi Sankyo, Novartis, Pfizer, MSD, Lilly; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Institutional, Local PI, multicenter study: Ipsen. A. Toss: Financial Interests, Personal, Invited Speaker: Eli-Lilly, Novartis; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Pfizer, Eli Lilly; Non-Financial Interests, Member: AIOM. A. Fontana: Financial Interests, Personal, Advisory Board: Novartis, Daiichi Sankyo, Eli Lilly, Seagen, MSD, AstraZeneca; Financial Interests, Personal, Writing Engagement: Pfizer. M. Lambertini: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Lilly, Novartis, Pfizer, Exact Sciences, MSD, Seagen, Gilead; Financial Interests, Personal, Invited Speaker: Takeda, Sandoz, Ipsen, Libbs, Knight, Daiichi Sankyo, Lilly, Pfizer, Novartis, Roche; Financial Interests, Personal, Other, Travel grant to attend ASCO 2022: Gilead; Financial Interests, Institutional, Coordinating PI, 2-year research grant paid to my Institution: Gilead. N. Bianco: Financial Interests, Institutional, Writing Engagement: Roche. P. Vici: Financial Interests, Personal, Advisory Board: Novartis, Eisai, Pfizer, Lilly; Financial Interests, Institutional, Local PI, multicentric trial (Persevera): Roche; Financial Interests, Institutional, Local PI, multicentric study (LIDERA): Roche; Financial Interests, Institutional, Local PI, EPIK B2: Novartis. A. Gennari: Financial Interests, Personal, Invited Speaker: Eisai, Lilly; Financial Interests, Personal, Advisory Board: Eisai, Novartis, AstraZeneca, Roche, Gentili, Daiichi Sankyo, Pfizer, Lilly. L. Cortesi: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD; Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Gilead. E. Bria: Financial Interests, Personal, Advisory Board: AZ, Roche, BMS, MSD, Eli-Lilly, Amgen, Pfizer, Novartis; Financial Interests, Personal, Invited Speaker: AZ, Roche, BMS, MSD, Eli-Lilly, Pfizer, Novartis; Financial Interests, Institutional, Research Grant: AZ, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
479P - Radiomics to predict HER2 status in breast cancer brain metastases
Presenter: Gaia Griguolo
Session: Poster session 04
480P - Prognostic significance of somatic DNA gene rearrangement and structural atypia in metastatic breast cancer
Presenter: Hiroshi Tada
Session: Poster session 04
481P - Second generation oral selective estrogen receptor degraders (SERDs) in breast cancer: A systematic review and meta-analysis of clinical trials
Presenter: Maysa Silveira Vilbert
Session: Poster session 04
482P - Precision imaging with human epidermal growth factor receptor 2-positron emission tomography (HER2-PET) for refined treatment selection in patients with HER2-low breast cancer
Presenter: Siri af Burén
Session: Poster session 04
483P - Prognostic value of androgen receptor expression in patients with advanced triple-negative metastatic breast cancer treated with sacituzumab govitecan: A French multicentre retrospective study
Presenter: Monica Arnedos
Session: Poster session 04
484P - Multi-platform characterization of HER2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04
485P - A novel approach to identify subpopulation of CTCs with metastatic potential using sc-RNA-seq
Presenter: Evgeniya Grigoryeva
Session: Poster session 04
486P - The influence of NF1 germline and somatic mutations on breast cancer patient survival
Presenter: Roope Kallionpää
Session: Poster session 04
487P - Induction of an inflammatory tumor microenvironment with oncolytic virus CF33-hNIS-antiPD-L1 intratumoral injection in patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Jamie Rand
Session: Poster session 04
488P - Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population
Presenter: Qianyi Lu
Session: Poster session 04